According to BeiGene 's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 6.28066. At the end of 2023 the company had a P/S ratio of 8.06.
Year | P/S ratio | Change |
---|---|---|
2023 | 8.06 | -51.36% |
2022 | 16.6 | -29.1% |
2021 | 23.4 | -69.96% |
2020 | 77.8 | 223.81% |
2019 | 24.0 | -42.86% |
2018 | 42.0 | 125.23% |
2017 | 18.7 | -98.34% |
2016 | > 1000 |
Company | P/S ratio | P/S ratio differencediff. | Country |
---|---|---|---|
OPKO Health
OPK | 1.01 | -83.94% | ๐บ๐ธ USA |
Onconova Therapeutics ONTX | 92.5 | 1,372.75% | ๐บ๐ธ USA |